Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.

Front Oncol · 2016 · PMC4904019 · PMID 27379204

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Treatment of animals with ruxolitinib alone or MMF alone did not alter tumor growth whatsoever, and treatment of animals with afatinib alone showed a trend for reduced BT474 tumor growth that was not statistically significant (Figure 7 B, not shown).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.